Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics Inc. (ADMA) is a commercial-stage biopharmaceutical company advancing plasma-derived therapies for immune deficiencies and infectious diseases. This dedicated news hub provides verified updates on corporate developments, regulatory milestones, and clinical progress.
Investors and healthcare professionals will discover timely coverage of earnings announcements, FDA decisions, manufacturing innovations, and strategic partnerships. Our curated selection emphasizes ADMA’s operational achievements in plasma collection, biomanufacturing excellence, and therapeutic pipeline advancements.
Key updates include product authorization progress, financial disclosures, patent developments, and peer-reviewed research findings. All content undergoes rigorous verification to ensure accuracy for investment and industry analysis.
Bookmark this page for direct access to ADMA’s official communications and expertly contextualized news. Maintain awareness of critical developments impacting this innovative biologics manufacturer through Stock Titan’s trusted reporting.
ADMA Biologics has announced the opening of a new plasma collection facility in Maryville, Tennessee, which is part of its strategy to enhance plasma supply chain control. The facility is designed to support increased plasma collection throughput as the company aims to establish a self-sufficient supply chain. ADMA has submitted a Biologics License Application (BLA) for this center to the FDA, expecting a decision by Q4 2021. The facility will be equipped with advanced technology to improve donor experience and will employ 50 trained staff members.
ADMA Biologics (Nasdaq: ADMA) announced that its President and CEO, Adam Grossman, will participate in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, at 7:55 a.m. ET. The event will be accessible via a webcast on the company's website, archived for 90 days post-event.
ADMA is focused on developing specialty plasma-derived biologics for immune-compromised patients and markets three FDA-approved products: BIVIGAM®, ASCENIV™, and NABI-HB®. The company operates a plasma fractionation facility in Boca Raton, Florida.
ADMA Biologics reported total revenues of $28.3 million for the first nine months of 2020, a 63% increase year-over-year. The third quarter generated $10.3 million, marking a 42% growth compared to Q3 2019. Despite revenue growth, net loss for the quarter was $16.9 million, attributed to rising costs and increased operational expenses. The company is ahead of schedule in expanding its plasma collection centers, aiming for five to ten new centers by 2025. ADMA's cash reserves rose to $59.7 million as of September 30, 2020.
ADMA Biologics announced a live conference call on November 5, 2020, at 4:30 p.m. ET, to discuss its Q3 2020 financial results and business highlights. The call will be accessible via phone and an audio webcast, with an archived version available two hours post-event. ADMA specializes in manufacturing and marketing plasma-derived biologics, including ASCENIV™, BIVIGAM®, and NABI-HB®, approved by the FDA for treating immunodeficient patients. More information can be found on their website.
ADMA Biologics, Inc. (Nasdaq: ADMA) is hosting an exclusive educational event at IDWeek 2020 on respiratory viral infections, featuring experts Dr. Michael Ison and Dr. Lisa Forbes Satter. The session on October 22 will focus on managing infections in immunocompromised patients. Additionally, new data on Streptococcus pneumoniae will be presented in an on-demand session. ADMA Biologics develops specialty plasma-derived biologics for immunodeficient patients, with FDA-approved products including ASCENIV™, BIVIGAM®, and NABI-HB® to combat infectious diseases.
ADMA Biologics, a biopharmaceutical company, will have its CEO Adam Grossman participate in a fireside chat at the Morgan Stanley Virtual Healthcare Conference on September 14, 2020, at 4:30 p.m. ET. This event will provide insights into the company's operations and product offerings, focusing on specialty plasma-derived biologics for immunodeficient patients. A webcast of the event will be available on the ADMA website and archived for 90 days. ADMA manufactures three FDA-approved products for treating immune deficiencies and infectious diseases.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in several investor conferences in September 2020. The events include the H.C. Wainwright 22nd Annual Global Investment Conference on September 14 at 2:30 p.m. ET, Cantor Virtual Global Healthcare Conference on September 17 at 11:20 a.m. ET, and Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 22 at 9:10 a.m. ET. Webcasts will be available on ADMA's website and archived for 90 days.
ADMA Biologics reported $18 million in total revenues for the first half of 2020, reflecting a 78% increase year-over-year. Despite a 19% revenue growth in Q2 compared to 2019, the company faced disruptions due to COVID-19, affecting product testing and supply chains. ADMA opened a new plasma center and joined the CoVIg-19 Plasma Alliance. It anticipates generating $250 million in annual revenue within three to five years. However, net loss for Q2 reached $20.2 million, up from $13.2 million in Q2 2019, driven by increased operational costs.
ADMA Biologics, Inc. (ADMA) announced a live conference call scheduled for August 5, 2020, at 4:30 p.m. ET to discuss its business highlights and financial results for Q2 2020, ending June 30, 2020. The call can be accessed via phone or through an audio webcast available on ADMA's investor relations website. The company is focused on manufacturing and developing plasma-derived biologics targeting immunodeficient patients.
ADMA Biologics announced the opening of its second plasma collection facility, ADMA BioCenters, in Knoxville, TN. This facility is part of ADMA's plan to establish 5 to 10 new centers by the end of 2022. A Biologics License Application (BLA) has been submitted to the FDA for approval, expected by mid-2021. The Knoxville center features modern equipment and amenities to enhance donor experience. Until FDA approval, ADMA can collect plasma, which will then be used for production of its FDA-approved immunoglobulin products.
